Abiomed 公司(纳斯达克编号:ABMD)是突破性心脏支架技术的领先供应商,它今天宣布 2017 财年第四季度收入达到 1.247 亿美元,比 2016 年同期的 9,400 万美元收入增长 33%。2017 财年的总收入为 4.453 亿美元,比 2016 年的 3.295 亿美元收入增长 35%。
Abiomed, Inc. and Subsidiaries | |||||||||
Consolidated Balance Sheets | |||||||||
(Unaudited) | |||||||||
(in thousands, except share data) | |||||||||
March 31, 2017 | March 31, 2016 | ||||||||
ASSETS | |||||||||
Current assets: | |||||||||
Cash and cash equivalents | $ | 39,040 | $ | 48,231 | |||||
Short-term marketable securities | 190,908 | 163,822 | |||||||
Accounts receivable, net | 54,055 | 42,821 | |||||||
Inventories | 34,931 | 26,740 | |||||||
Prepaid expenses and other current assets | 8,024 | 6,778 | |||||||
Total current assets | 326,958 | 288,392 | |||||||
Long-term marketable securities | 47,143 | 1,000 | |||||||
Property and equipment, net | 87,777 | 23,184 | |||||||
Goodwill | 31,045 | 33,003 | |||||||
In-process research and development | 14,482 | 15,396 | |||||||
Long-term deferred tax assets, net | 34,723 | 58,534 | |||||||
Other assets | 8,286 | 4,422 | |||||||
Total assets | $ | 550,414 | $ | 423,931 | |||||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||
Current liabilities: | |||||||||
Accounts payable | $ | 20,620 | $ | 9,381 | |||||
Accrued expenses | 37,703 | 28,382 | |||||||
Deferred revenue | 10,495 | 8,778 | |||||||
Current portion of capital lease obligation | 799 | — | |||||||
Total current liabilities | 69,617 | 46,541 | |||||||
Other long-term liabilities | 3,251 | 220 | |||||||
Contingent consideration | 9,153 | 7,563 | |||||||
Long-term deferred tax liabilities | 783 | 832 | |||||||
Capital lease obligation, net of current portion | 15,539 | — | |||||||
Total liabilities | 98,343 | 55,156 | |||||||
Commitments and contingencies | |||||||||
Stockholders' equity: | |||||||||
Class B Preferred Stock, $.01 par value | — | — | |||||||
Authorized - 1,000,000 shares; Issued and outstanding - none | |||||||||
Common stock, $.01 par value | 437 | 426 | |||||||
Authorized - 100,000,000 shares; Issued - 45,249,281 shares at March 31, 2017 and 43,973,119 shares at March 31, 2016; | |||||||||
Outstanding - 43,673,286 shares at March 31, 2017 and 42,596,228 shares at March 31, 2016 | |||||||||
Additional paid in capital | 565,962 | 508,624 | |||||||
Accumulated deficit | (46,959 | ) | (99,075 | ) | |||||
Treasury stock at cost - 1,575,995 shares at March 31, 2017 and 1,376,891 shares at March 31, 2016 | (46,763 | ) | (26,660 | ) | |||||
Accumulated other comprehensive loss | (20,606 | ) | (14,540 | ) | |||||
Total stockholders' equity | 452,071 | 368,775 | |||||||
Total liabilities and stockholders' equity | $ | 550,414 | $ | 423,931 | |||||
Abiomed, Inc. and Subsidiaries | ||||||||||||||
Consolidated Statements of Operations | ||||||||||||||
(Unaudited) | ||||||||||||||
(in thousands, except per share data) | ||||||||||||||
Three Months Ended March 31, |
Fiscal Years Ended March 31, |
|||||||||||||
2017 | 2016 | 2017 | 2016 | |||||||||||
Revenue: | ||||||||||||||
Product revenue | $ | 124,654 | $ | 93,951 | $ | 445,195 | $ | 329,520 | ||||||
Funded research and development | 26 | 6 | 109 | 23 | ||||||||||
124,680 | 93,957 | 445,304 | 329,543 | |||||||||||
Costs and expenses: | ||||||||||||||
Cost of product revenue | 19,261 | 14,663 | 70,627 | 50,419 | ||||||||||
Research and development | 16,325 | 14,225 | 66,386 | 49,759 | ||||||||||
Selling, general and administrative | 60,100 | 45,256 | 218,153 | 164,261 | ||||||||||
95,686 | 74,144 | 355,166 | 264,439 | |||||||||||
Income from operations | 28,994 | 19,813 | 90,138 | 65,104 | ||||||||||
Other income: | ||||||||||||||
Investment income, net | 486 | 186 | 1,554 | 395 | ||||||||||
Other (expense) income, net | (124 | ) | 228 | (349 | ) | 339 | ||||||||
362 | 414 | 1,205 | 734 | |||||||||||
Income before income taxes | 29,356 | 20,227 | 91,343 | 65,838 | ||||||||||
Income tax provision | 14,457 | 9,229 | 39,227 | 27,691 | ||||||||||
Net income | $ | 14,899 | $ | 10,998 | $ | 52,116 | $ | 38,147 | ||||||
Basic net income per share | $ | 0.34 | $ | 0.26 | $ | 1.21 | $ | 0.90 | ||||||
Basic weighted average shares outstanding | 43,579 | 42,463 | 43,238 | 42,204 | ||||||||||
Diluted net income per share | $ | 0.33 | $ | 0.24 | $ | 1.17 | $ | 0.85 | ||||||
Diluted weighted average shares outstanding | 44,924 | 45,112 | 44,658 | 44,895 |
如需了解更多信息,请联系: 英格丽德·戈德堡(Ingrid Goldberg) 投资者关系部总监 978-646-1590 ir@abiomed.com 阿德里安娜·史密斯(Adrienne Smith) 公共关系部高级总监 978-646-1553 adsmith@abiomed.com
新闻热点
新闻爆料